AU2002330998A1 - Benzoquinone ansamycins - Google Patents

Benzoquinone ansamycins

Info

Publication number
AU2002330998A1
AU2002330998A1 AU2002330998A AU2002330998A AU2002330998A1 AU 2002330998 A1 AU2002330998 A1 AU 2002330998A1 AU 2002330998 A AU2002330998 A AU 2002330998A AU 2002330998 A AU2002330998 A AU 2002330998A AU 2002330998 A1 AU2002330998 A1 AU 2002330998A1
Authority
AU
Australia
Prior art keywords
benzoquinone ansamycins
ansamycins
benzoquinone
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2002330998A
Inventor
Li Feng
C. Richard Hutchinson
Robert Johnson
David C. Myles
Daniel Santi
Zong-Qiang Tian
Yi-Qing Zhou
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Kosan Biosciences Inc
Original Assignee
Kosan Biosciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kosan Biosciences Inc filed Critical Kosan Biosciences Inc
Publication of AU2002330998A1 publication Critical patent/AU2002330998A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/08—Bridged systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D225/00—Heterocyclic compounds containing rings of more than seven members having one nitrogen atom as the only ring hetero atom
    • C07D225/04—Heterocyclic compounds containing rings of more than seven members having one nitrogen atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D225/06—Heterocyclic compounds containing rings of more than seven members having one nitrogen atom as the only ring hetero atom condensed with carbocyclic rings or ring systems condensed with one six-membered ring

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU2002330998A 2001-08-06 2002-08-05 Benzoquinone ansamycins Abandoned AU2002330998A1 (en)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US31007901P 2001-08-06 2001-08-06
US60/310,079 2001-08-06
US60/389,255 2002-06-01
US38925502P 2002-06-14 2002-06-14
US39392902P 2002-07-03 2002-07-03
US60/393,929 2002-07-03
US39527502P 2002-07-12 2002-07-12
PCT/US2002/024891 WO2003013430A2 (en) 2001-08-06 2002-08-05 Benzoquinone ansamycins
USNOTGIVEN 2003-10-16

Publications (1)

Publication Number Publication Date
AU2002330998A1 true AU2002330998A1 (en) 2003-02-24

Family

ID=31982570

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2002330998A Abandoned AU2002330998A1 (en) 2001-08-06 2002-08-05 Benzoquinone ansamycins

Country Status (3)

Country Link
EP (1) EP1420747A4 (en)
AU (1) AU2002330998A1 (en)
WO (1) WO2003013430A2 (en)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7189549B2 (en) 2002-06-14 2007-03-13 Kosan Biosciences, Inc. Recombinant polynucleotides encoding pro-geldanamycin producing polyketide synthase and accessory proteins, and uses thereof
KR20050119665A (en) * 2003-03-28 2005-12-21 코산 바이오사이언시즈, 인코포레이티드 Devices, methods, and compositions to prevent restenosis
US20050020534A1 (en) * 2003-05-30 2005-01-27 Kosan Biosciences, Inc. Method for treating diseases using HSP90-inhibiting agents in combination with antimetabolites
US20050020557A1 (en) * 2003-05-30 2005-01-27 Kosan Biosciences, Inc. Method for treating diseases using HSP90-inhibiting agents in combination with enzyme inhibitors
US6875863B1 (en) 2003-11-12 2005-04-05 Kosan Biosciences, Inc. 11-O-methylgeldanamycin compounds
US6887993B1 (en) 2003-11-12 2005-05-03 Kosan Biosciences, Inc. 11-O-methylgeldanamycin compounds
US6870049B1 (en) 2003-11-12 2005-03-22 Kosan Biosciences, Inc. 11-O-methylgeldanamycin compounds
US6855705B1 (en) 2003-11-12 2005-02-15 Kosan Biosciences, Inc. 11-O-methylgeldanamycin compounds
DK1716119T3 (en) 2003-12-23 2013-06-10 Infinity Discovery Inc ANALOGS OF BENZOQUINON-CONTAINING ANAMICYCINES FOR TREATMENT OF CANCER
US20060019941A1 (en) * 2003-12-23 2006-01-26 Infinity Pharmaceuticals, Inc. Analogs of benzoquinone-containing ansamycins and methods of use thereof
US7259156B2 (en) * 2004-05-20 2007-08-21 Kosan Biosciences Incorporated Geldanamycin compounds and method of use
ES2594874T3 (en) 2004-11-18 2016-12-23 Synta Pharmaceuticals Corp. Triazole compounds that modulate the activity of HSP90
AU2006263111A1 (en) * 2005-06-29 2007-01-04 Kyowa Hakko Kirin Co., Ltd. Benzenoid ansamycin derivative
JP5118039B2 (en) 2005-08-18 2013-01-16 シンタ ファーマシューティカルズ コーポレーション Triazole compounds that modulate HSP90 activity
US8426355B2 (en) 2006-03-15 2013-04-23 Theralogics, Inc. Methods of treating muscular wasting diseases using NF-κB activation inhibitors
US20110091452A1 (en) * 2006-03-31 2011-04-21 Christine Martin 4,5-Dihydromacbecin Derivatives and Their Use in the Treatment of Cancer or B-Cell Malignancies
GB0606542D0 (en) * 2006-03-31 2006-05-10 Biotica Tech Ltd Novel compounds and methods for their production
US8916552B2 (en) 2006-10-12 2014-12-23 Astex Therapeutics Limited Pharmaceutical combinations
EP2073807A1 (en) 2006-10-12 2009-07-01 Astex Therapeutics Limited Pharmaceutical combinations
PE20081506A1 (en) 2006-12-12 2008-12-09 Infinity Discovery Inc ANSAMYCIN FORMULATIONS
KR20100074177A (en) 2007-09-10 2010-07-01 유니버시티 오브 매사추세츠 Mitochondria-targeted anti-tumour agents
CN101220068B (en) * 2008-01-18 2012-06-13 中国医学科学院医药生物技术研究所 A set of geldanamycin derivant and method for preparing the same
ES2347619B1 (en) * 2008-05-13 2011-09-15 Consejo Superior De Investigaciones Cientificas (Csic) (50%) PROCEDURE TO DESIGN AN ANTITUMORAL INDIVIDUAL THERAPY BASED ON THE DETECTION OF HSP90 PROTEIN LEVELS, THE USE OF HSP90 PROTEIN INHIBITORS FOR THE PREPARATION OF PHARMACEUTICAL COMPOSITIONS, THE COMPOSITIONS AS OBTAINED AND THEIR APPLICATIONS.
CN102245021B (en) 2008-10-15 2014-09-17 无限药品公司 Ansamycin hydroquinone compositions
WO2011133520A1 (en) 2010-04-19 2011-10-27 Synta Pharmaceuticals Corp. Cancer therapy using a combination of a hsp90 inhibitory compounds and a egfr inhibitor
AU2012332424A1 (en) 2011-11-02 2014-06-05 Synta Pharmaceuticals Corp. Combination therapy of Hsp90 inhibitors with platinum-containing agents
AU2012332421A1 (en) 2011-11-02 2014-06-05 Synta Pharmaceuticals Corp. Cancer therapy using a combination of Hsp90 inhibitors with topoisomerase I inhibitors
US9402831B2 (en) 2011-11-14 2016-08-02 Synta Pharmaceutical Corp. Combination therapy of HSP90 inhibitors with BRAF inhibitors
CN112679374A (en) * 2021-01-12 2021-04-20 湖南复瑞生物医药技术有限责任公司 Preparation method of 2-fluoro-6- (trifluoromethyl) benzamide

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4261989A (en) * 1979-02-19 1981-04-14 Kaken Chemical Co. Ltd. Geldanamycin derivatives and antitumor drug
JPS55111419A (en) * 1979-02-20 1980-08-28 Kaken Pharmaceut Co Ltd Antitumorigenic agent
EP0706516A1 (en) * 1993-06-29 1996-04-17 Pfizer Inc. Ansamycin derivatives as antioncogene and anticancer agents

Also Published As

Publication number Publication date
EP1420747A4 (en) 2010-06-02
EP1420747A2 (en) 2004-05-26
WO2003013430A3 (en) 2004-03-04
WO2003013430A2 (en) 2003-02-20

Similar Documents

Publication Publication Date Title
AU2002330998A1 (en) Benzoquinone ansamycins
AU2002313565A1 (en) Putter-heads
AU2002319532A1 (en) Feeding-bottles
AU2002330025A1 (en) Atlastin
AU2002313943A1 (en) Electromobile
AU2002226571A1 (en) Biligands
AU2001100406A4 (en) DriverSMS
AU2002313073A1 (en) Phytocystatin
AU2002257925A1 (en) Numberplates
AU2001100532A4 (en) FonePark
AU2001100338A4 (en) Sunglove
AU2002100746A4 (en) Adrail
AU2001100522A4 (en) e-Trans
AU2001100214A4 (en) Dolly-trolley
AU2002258599A1 (en) Anti-psychosis combination
AUPR899701A0 (en) Improved sign
AUPR409801A0 (en) Improvements
AUPR243601A0 (en) Improvements
AUPR237701A0 (en) La sachee
AU2002307690A1 (en) Cookpot
AU2002300330A1 (en) Spiralnet
AU2002314172A1 (en) Bis-piperidines
AU2002316748A1 (en) S-6-hydroxy-buspirone
AU2002319649A1 (en) R-6-hydroxy-buspirone
AU2002321547A1 (en) Beta-ketophosphonates

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase